99 related articles for article (PubMed ID: 6820139)
1. In vitro and in vivo behaviour of four different 99(m)Tc-HEDP complexes.
Inoue O; Yamaguchi T; Ikeda I
Nuklearmedizin; 1982 Dec; 21(6):227-31. PubMed ID: 6820139
[TBL] [Abstract][Full Text] [Related]
2. Preparation and biological distribution of technetium diphosphonate radiotracers synthesized without stannous ion.
Deutsch E; Libson K; Becker CB; Francis MD; Tofe AJ; Ferguson DL; McCreary LD
J Nucl Med; 1980 Sep; 21(9):859-66. PubMed ID: 6774066
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of two different HEDP content kits: stability study against dilution both in vivo and in vitro.
Inoue O; Ikeda I; Kurata K
Nuklearmedizin; 1982 Jun; 21(3):121-5. PubMed ID: 6813826
[TBL] [Abstract][Full Text] [Related]
4. Complexes of technetium with pyrophosphate, etidronate, and medronate.
Russell CD; Cash AG
J Nucl Med; 1979 Jun; 20(6):532-7. PubMed ID: 43885
[TBL] [Abstract][Full Text] [Related]
5. 99mTc-labelled compounds prepared with sodium dithionite as reducing agent.
Vilcek S; Kalincák M; Machán V
Nuklearmedizin; 1981 Dec; 20(6):283-9. PubMed ID: 6460222
[TBL] [Abstract][Full Text] [Related]
6. Complexes of technetium with hydroxycarboxylic acids: gluconic, glucoheptonic, tartaric, and citric.
Russell CD; Speiser AG
J Nucl Med; 1980 Nov; 21(11):1086-90. PubMed ID: 7431109
[TBL] [Abstract][Full Text] [Related]
7. Complexing of reduced technetium and tin(II) by chelating phosphate compounds. II. In vitro stability of pyrophosphate and ethane-1, hydroxy-1, diphosphonate (EHDP) complexes.
Schümichen C; Hohloch M; Hoffmann G
Nuklearmedizin; 1979 May; 18(2):105-9. PubMed ID: 38437
[TBL] [Abstract][Full Text] [Related]
8. Chemistry of technetium radiopharmaceuticals. I. Exploration of the tissue distribution and oxidation state consequences of technetium (IV) in Tc-Sn-gluconate and Tc-Sn-EHDP using carrier 99Tc.
Hambright P; McRae J; Valk PE; Bearden AJ; Shipley BA
J Nucl Med; 1975 Jun; 16(6):478-82. PubMed ID: 808594
[TBL] [Abstract][Full Text] [Related]
9. Aqueous chemistry of the vanadium(III) (V(III)) and the V(III)-dipicolinate systems and a comparison of the effect of three oxidation states of vanadium compounds on diabetic hyperglycemia in rats.
Buglyó P; Crans DC; Nagy EM; Lindo RL; Yang L; Smee JJ; Jin W; Chi LH; Godzala Iii ME; Willsky GR
Inorg Chem; 2005 Jul; 44(15):5416-27. PubMed ID: 16022540
[TBL] [Abstract][Full Text] [Related]
10. In vitro stabilization of a low-tin bone-imaging agent (99mTc-Sn-HEDP) by ascorbic acid.
Tofe AJ; Francis MD
J Nucl Med; 1976 Sep; 17(9):820-5. PubMed ID: 822138
[TBL] [Abstract][Full Text] [Related]
11. Effect of reaction conditions on preparations of rhenium-188 hydroxyethylidene diphosphonate complexes.
Lin WY; Hsieh JF; Lin CP; Hsieh BT; Ting G; Wang SJ; Knapp FF
Nucl Med Biol; 1999 May; 26(4):455-9. PubMed ID: 10382850
[TBL] [Abstract][Full Text] [Related]
12. In vivo distribution of Tc-99m(Sn)pyridoxylideneisoleucine: effects of storage and labeling conditions. Concise communication.
Kato M
J Nucl Med; 1979 Nov; 20(11):1189-93. PubMed ID: 536780
[TBL] [Abstract][Full Text] [Related]
13. Preparation, characterization, and biological evaluation of technetium(V) and rhenium(V) complexes of novel heterocyclic tetradentate N3S ligands.
Rajagopalan R; Grummon GD; Bugaj J; Hallemann LS; Webb EG; Marmion ME; Vanderheyden JL; Srinivasan A
Bioconjug Chem; 1997; 8(3):407-15. PubMed ID: 9177848
[TBL] [Abstract][Full Text] [Related]
14. Chemistry of 99mTc tracers. II. In vitro conversion of tagged HEDP and pyrophosphate (bone-seekers) into gluconate (renal agent). Effects of Ca and Fe (ii) on in vivo distribution.
McRae J; Hambright P; Valk P; Bearden AJ
J Nucl Med; 1976 Mar; 17(3):208-11. PubMed ID: 175138
[TBL] [Abstract][Full Text] [Related]
15. In vivo distributions of some component fractions of Tc(NaBH4)-HEDP mixtures separated by anion exchange high performance liquid chromatography.
Pinkerton TC; Ferguson DL; Deutsch E; Heineman WR; Libson K
Int J Appl Radiat Isot; 1982 Oct; 33(10):907-15. PubMed ID: 6818160
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of three diphosphonates: in vitro adsorption (C- 14 labeled) and in vivo osteogenic uptake (Tc-99m complexed).
Francis MD; Ferguson DL; Tofe AJ; Bevan JA; Michaels SE
J Nucl Med; 1980 Dec; 21(12):1185-9. PubMed ID: 6449567
[TBL] [Abstract][Full Text] [Related]
17. Modeling and spectroscopic studies of bisphosphonate-bone interactions. The Raman, NMR and crystallographic investigations of Ca-HEDP complexes.
Cukrowski I; Popović L; Barnard W; Paul SO; van Rooyen PH; Liles DC
Bone; 2007 Oct; 41(4):668-78. PubMed ID: 17644459
[TBL] [Abstract][Full Text] [Related]
18. 99mTc-labelled Cu(I)-EHDP, a potential skeletal imaging agent.
Agha NH; Al-Hilli AM; Hassen HA
Nuklearmedizin; 1981 Dec; 20(6):299-304. PubMed ID: 6799937
[TBL] [Abstract][Full Text] [Related]
19. Investigation of two new [99mTc]Tc-HEDP preparations that can be expected to give a better lesion-to-normal-bone uptake ratio when used as bone scanning agents.
de Ligny CL; Gelsema WJ; Hoevelaken TP; Schuring J
Nucl Med Biol; 1993 Jan; 20(1):23-9. PubMed ID: 8461877
[TBL] [Abstract][Full Text] [Related]
20. Complexing of Tc-99m with cyclam: concise communication.
Troutner DE; Simon J; Ketring AR; Volkert W; Holmes RA
J Nucl Med; 1980 May; 21(5):443-8. PubMed ID: 7373414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
